Design Therapeutics (DSGN) Common Equity (2020 - 2026)

Design Therapeutics has disclosed Common Equity across 7 years of filings, most recently posting $218.1 million for Q1 2026.

• Common Equity for Q1 2026 came in at $218.1 million, down 4.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $218.1 million (down 4.33% YoY), and the FY2025 annual result was $212.5 million, down 12.22% from the prior year.
• Common Equity came in at $218.1 million for Q1 2026 at Design Therapeutics, up from $212.5 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $370.3 million in Q1 2022 to a low of $199.7 million in Q3 2025.
• The 5-year median for Common Equity is $269.6 million (2024), against an average of $274.4 million.
• Across the five-year window, Common Equity declined 20.89% in 2025 and retreated 4.33% in 2026, its largest moves.
• Design Therapeutics' Common Equity stood at $327.3 million in 2022, then fell by 15.16% to $277.7 million in 2023, then fell by 12.82% to $242.1 million in 2024, then declined by 12.22% to $212.5 million in 2025, then increased by 2.61% to $218.1 million in 2026.
• The last three Common Equity figures came in at $218.1 million (Q1 2026), $212.5 million (Q4 2025), and $199.7 million (Q3 2025), per Business Quant data.